Verdence Capital Advisors LLC Sells 4,142 Shares of Merck & Co., Inc. $MRK

Verdence Capital Advisors LLC lowered its position in Merck & Co., Inc. (NYSE:MRK) by 8.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 45,379 shares of the company’s stock after selling 4,142 shares during the period. Verdence Capital Advisors LLC’s holdings in Merck & Co., Inc. were worth $6,594,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of MRK. Aegis Wealth Management Inc. boosted its stake in shares of Merck & Co., Inc. by 1.4% in the 3rd quarter. Aegis Wealth Management Inc. now owns 8,718 shares of the company’s stock valued at $1,267,000 after purchasing an additional 119 shares during the last quarter. Patton Albertson Miller Group LLC raised its stake in Merck & Co., Inc. by 17.3% during the third quarter. Patton Albertson Miller Group LLC now owns 46,821 shares of the company’s stock worth $6,804,000 after buying an additional 6,898 shares during the last quarter. Westover Capital Advisors LLC raised its stake in Merck & Co., Inc. by 8.9% during the third quarter. Westover Capital Advisors LLC now owns 12,763 shares of the company’s stock worth $1,855,000 after buying an additional 1,047 shares during the last quarter. Blume Capital Management Inc. raised its stake in Merck & Co., Inc. by 32.4% during the third quarter. Blume Capital Management Inc. now owns 1,854 shares of the company’s stock worth $269,000 after buying an additional 454 shares during the last quarter. Finally, Motive Wealth Advisors raised its stake in Merck & Co., Inc. by 11.0% during the third quarter. Motive Wealth Advisors now owns 2,744 shares of the company’s stock worth $399,000 after buying an additional 271 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $140.36 on Tuesday. The stock has a market capitalization of $346.28 billion, a price-to-earnings ratio of 112.29, a PEG ratio of 6.74 and a beta of 0.21. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock’s 50 day moving average price is $146.69 and its two-hundred day moving average price is $125.84.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 2.64 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were paid a dividend of $0.85 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.4%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and partner Daiichi Sankyo reported positive Phase 3 results for sacituzumab tirumotecan (Sac-TMT) in certain patients with advanced or recurrent endometrial cancer. The treatment reduced the risk of death by 32% and the risk of disease progression or death by 41% versus chemotherapy; median overall survival was 19 months compared with 12.1 months. An FDA decision is expected by June 2027. Sac-TMT Phase 3 results
• Positive Sentiment: KEYTRUDA monotherapy reduced the risk of disease progression or death by 43% in a specified group of patients with mismatch repair-deficient endometrial cancer, reinforcing the drug’s oncology franchise and potential for additional indications. KEYTRUDA endometrial cancer results
• Positive Sentiment: Barclays raised its MRK price target to $180 from $150 and maintained an overweight rating. Another valuation update lifted fair value to $159.76 from $155.68, citing Merck’s oncology pipeline and cancer-vaccine partnership. Barclays price-target increase
• Neutral Sentiment: Merck and Moderna’s personalized melanoma vaccine reduced recurrence or death by 42% when added to KEYTRUDA in a Phase 3 trial. However, the result was below some elevated investor expectations, and overall-survival data remain immature. Merck’s October 29 earnings call may provide details on regulatory filings, launch economics and the vaccine’s role in offsetting future Keytruda losses.
• Negative Sentiment: Investors remain focused on Keytruda’s compound-patent expiration in December 2028. Upcoming results must show that newer products—including Winrevair, Keytruda QLEX and other pipeline assets—can support management’s “shallow dip” outlook.
• Negative Sentiment: New U.S. Treasury restrictions on certain U.S. collaborations and investments involving Chinese biotech companies could limit Merck’s access to partnerships, research and potential cancer-drug candidates from China. China biotech restrictions and Merck

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Argus increased their price target on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Barclays lifted their price objective on Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an “overweight” rating in a research report on Monday. The Goldman Sachs Group boosted their price objective on Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Finally, UBS Group boosted their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Seventeen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $153.12.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 20,784 shares of Merck & Co., Inc. stock in a transaction on Monday, August 10th. The shares were sold at an average price of $130.43, for a total value of $2,710,857.12. Following the completion of the sale, the executive vice president directly owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. This represents a 63.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock valued at $29,977,783 over the last 90 days. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.